ArticleBMC gastroenterology2025
Bioinformatics analysis and in vitro studies identify COX7C as a prognostic predictor in gastric adenocarcinoma.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundStomach adenocarcinoma (STAD) remains a significant threat to human health. This study sought to discover clinically relevant biomarkers for STAD by integrating bioinformatics analysis and in vitro experimental methods.
methodsWe utilized the GSE64951 dataset to screen for differentially expressed genes (DEGs), which were then subjected to weighted gene co-expression network analysis (WGCNA). Candidate modules were subjected to Molecular Complex Detection (MCODE) analysis to extract key genes. Survival analysis and immune infiltration analysis were conducted to identify hub genes associated with STAD prognosis. Among them, cytochrome c oxidase subunit 7 C (COX7C) was selected for further investigation. Its expression levels in normal versus tumor tissues were compared, and its diagnostic performance was assessed via receiver operating characteristic (ROC) curve analysis. Functional experiments, including COX7C overexpression and knockdown, were performed in MGC803 cells to evaluate its effects on viability, apoptosis, migration, and invasion.
resultsWGCNA identified multiple gene modules, among which the blue and turquoise modules showed the strongest correlations with clinical traits and were selected for further analysis. MCODE analysis identified 11 key genes. COX7C was identified as hub gene, and its prognostic signature demonstrated robust predictive power. Gene Set Enrichment Analysis (GSEA) indicated that COX7C was significantly involved in pathways such as amino acid metabolism and non - alcoholic fatty liver disease. Notably, COX7C mRNA expression was significantly downregulated in STAD tissues (AUC = 0.7253, P = 0.0032). Functional experiments demonstrated that overexpression of COX7C significantly inhibited cell viability, promoted apoptosis, and reduced cell migration and invasion. Conversely, knockdown of COX7C led to opposite effects.
conclusionCOX7C functions as a tumor suppressor and a potential prognostic biomarker in STAD. These findings provide new insights into STAD pathogenesis and suggest COX7C as a promising target for improving diagnostic and therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.